Payment overview · 2025
General Payments
$745.60
37 reported records · 15 companies
Healthcare provider profile · identity verified
Laya Nasrallah, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DEARBORN, MI · NPI 1316562432
Verified facts
What the public records show
CMS Open Payments records show Laya Nasrallah, NP received $745.60 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.05 | 27.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.02 | 19.6% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.35 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.34 | 6.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.28 | 6.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.86 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.79 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.98 | 3.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.13 | 3.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.38 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.94 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.79 | 2.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.00 | 2.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $13.80 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.60 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $126.31 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.45 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.98 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $53.35 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.34 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 80 |
| Omeprazole | Omeprazole | 241 | 74 |
| Metformin Hcl | Metformin Hcl | 158 | 46 |
| Ibuprofen | Ibuprofen | 130 | 59 |
| Lisinopril | Lisinopril | 130 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 41 |
| Losartan Potassium | Losartan Potassium | 101 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 26 |
| Simvastatin | Simvastatin | 97 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 40 |
| Famotidine | Famotidine | 90 | 28 |
| Alprazolam | Alprazolam | 85 | 39 |
| Furosemide | Furosemide | 81 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 26 |
| Jardiance | Empagliflozin | 74 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 21 |
| Linzess | Linaclotide | 70 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 24 |
| Alendronate Sodium | Alendronate Sodium | 65 | 16 |
| Nystatin | Nystatin | 64 | 20 |
| Potassium Chloride | Potassium Chloride | 61 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | 17 |
| Gabapentin | Gabapentin | 54 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 14 |
| Ammonium Lactate | Ammonium Lactate | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 18 |
| Meclizine Hcl | Meclizine Hcl | 43 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 14 |
| Pregabalin | Pregabalin | 40 | 20 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Eliquis | Apixaban | 36 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 29 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 12 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 17 |
| Meloxicam | Meloxicam | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 14 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Glipizide | Glipizide | 28 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Naproxen | Naproxen | 21 | 11 |
| Ozempic | Semaglutide | 21 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.60 · 37 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, NURTEC ODT, OPSUMIT, OTEZLA, Ohtuvayre, REPATHA, TRINTELLIX, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error